Cargando…
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
BACKGROUND: Chimeric antigen receptor (CAR) T cells have achieved remarkable responses in patients with hematological malignancies; however, the potential of this therapeutic platform for solid tumors like glioblastoma (GBM) has been limited, due in large part to the targeting of single antigens in...
Autores principales: | Schmidts, Andrea, Srivastava, Ambike A, Ramapriyan, Rishab, Bailey, Stefanie R, Bouffard, Amanda A, Cahill, Daniel P, Carter, Bob S, Curry, William T, Dunn, Gavin P, Frigault, Matthew J, Gerstner, Elizabeth R, Ghannam, Jack Y, Kann, Michael C, Larson, Rebecca C, Leick, Mark B, Nahed, Brian V, Richardson, Leland G, Scarfò, Irene, Sun, Jing, Wakimoto, Hiroaki, Maus, Marcela V, Choi, Bryan D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896600/ https://www.ncbi.nlm.nih.gov/pubmed/36751672 http://dx.doi.org/10.1093/noajnl/vdac185 |
Ejemplares similares
-
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
por: Choi, Bryan D., et al.
Publicado: (2019) -
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018) -
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016) -
Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020) -
Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)